Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 6/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.56 |
| ▸ | FAAH | O00519 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10079339 | 1.00 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL13733359 | 1.00 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL22311909 | 1.00 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL16933147 | 1.00 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL27420754 | 1.00 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL15215618 | 1.00 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL17732171 | 1.00 | MGLL (0.71) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL5828798 | 0.98 | MGLL (0.68) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL18157046 | 0.90 | PTGS1 (0.62) | MGLLPTGS1PTGS2FAAHALDH1A1 | |
| SCHEMBL10126653 | 0.90 | MGLL (0.67) | MGLLPTGS1PTGS2FAAHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4659809-A2 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-3538539-B1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMA (US) | 2025-08-27 | — | — | EP | disclosed |
| US-12377159-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| WO-2025134068-A1 | ANTIBODY DRUG CONJUGATES TARGETING PROTEINOPATHIES, AND USES THEREOF | AC IMMUNE SA (CH) | 2025-06-26 | — | — | WO | disclosed |
| US-20250152722-A1 | DRUG CONJUGATE OF GLUCOCORTICOID | SHANGHAI SENHUI MEDICINE CO., LTD. (CN) | 2025-05-15 | — | — | US | disclosed |
| WO-2025064709-A1 | SURFACE-MODIFIED FIBERS AND ARTICLES AND METHODS OF MAKING THE SAME | ORIGIN MATERIALS OPERATING, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-4470569-A1 | DRUG CONJUGATE OF GLUCOCORTICOID | Shanghai Shengdi Pharmaceutical Co., Ltd (CN) | 2024-12-04 | — | — | EP | disclosed |
| US-20240293570-A1 | HIGHLY STABLE TARGETED LINKER-DRUG CONJUGATE | CHENGDU SCIMOUNT PHARMATECH CO., LTD. (CN) | 2024-09-05 | — | — | US | disclosed |
| EP-4420682-A1 | HIGHLY-STABLE TARGETED LINKER-DRUG CONJUGATE | Chengdu Scimount Pharmatech Co., Ltd. (CN) | 2024-08-28 | — | — | EP | disclosed |
| CN-118236514-A | Antibody-glucocorticoid conjugates and uses thereof | 津药生物科技（天津）有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2016203432-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| EP-3082877-A2 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | Novartis AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| WO-2016146638-A1 | CRYPTOPHYCIN-BASED ANTIBODY-DRUG CONJUGATES WITH NOVEL SELF-IMMOLATIVE LINKERS | EXIRIS S.R.L. (IT) | 2016-09-22 | — | — | WO | disclosed |
| EP-3069734-A1 | CRYPTOPHYCIN-BASED ANTIBODY-DRUG CONJUGATES WITH NOVEL SELF-IMMOLATIVE LINKERS | Exiris S.r.l. (IT) | 2016-09-21 | — | — | EP | disclosed |
| WO-2016071856-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS AG (CH) | 2016-05-12 | — | — | WO | disclosed |
| WO-2015095301-A2 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | IRM LLC (BM) | 2015-06-25 | — | — | WO | disclosed |
| EP-1603930-B1 | PROTEIN-BOUND DERIVATIVES OF PLATINUM COMPLEXES CONTAINING CYCLOBUTANE 1.1-DICARBOXYLLATE LIGANDS | KTB TUMORFORSCHUNGS GMBH (DE) | 2007-08-29 | — | — | EP | disclosed |
| US-7141691-B2 | Protein-bound derivatives of platinum complexes containing cyclobutane1, 1-dicarboxyllate ligands | KTB TUMORFORSCHUNGS GMBH (DE) | 2006-11-28 | — | — | US | disclosed |
| US-20060089341-A1 | Protein-bound derivatives of platinum complexes containing cyclobutane1,1-dicarboxyllate ligands | KTB TUMORFORSCHUNGS GMBH (DE) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089341-A1 | Protein-bound derivatives of platinum complexes containing cyclobutane1,1-dicarboxyllate ligands | DDB1, DCLRE1A, PDCD1LG2 | MGLL 4755/4885PTGS1 2109/4885PTGS2 3364/4885 |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, NGLY1, VIP | MGLL 4602/4885PTGS1 4232/4885PTGS2 4661/4885 |
| US-20250152722-A1 | DRUG CONJUGATE OF GLUCOCORTICOID | SHBG, CYP17A1, HSD17B7 | MGLL 2673/4885PTGS1 979/4885PTGS2 2340/4885 |
| US-12377159-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | MGLL 2400/4885PTGS1 740/4885PTGS2 1315/4885 |
| US-20240293570-A1 | HIGHLY STABLE TARGETED LINKER-DRUG CONJUGATE | DARS1, FCGR2A, CD44 | MGLL 4872/4885PTGS1 4460/4885PTGS2 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.